Larimar Submits Biologics License Application for Friedreich's Ataxia Treatment
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 37 minutes ago
0mins
Source: stocktwits
- FDA Meeting Outcome: Following a multidisciplinary Type B meeting with the FDA, Larimar submitted the first module of its biologics license application, with the FDA indicating that the existing data package may support accelerated approval, which sets the stage for future market access as the company plans to submit remaining modules in the second half of 2026.
- Clinical Data Highlights: Patients treated with nomlabofusp showed sustained increases in skin frataxin levels over one year, with all nine evaluable participants achieving frataxin levels above 50% of the average seen in healthy volunteers, demonstrating the treatment's efficacy and potential market competitiveness.
- Commercialization Plans: If approved, Larimar aims for a mid-2027 commercial launch of its treatment and plans to dose the first patient in its global confirmatory Phase 3 study in Q3 2026, indicating a proactive approach to future market positioning.
- Investor Sentiment: Despite a 4% decline in LRMR stock year-to-date, it has risen 19% over the past 12 months, with investor sentiment on Stocktwits trending in the 'extremely bullish' territory, reflecting optimism about the company's potential success.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LRMR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LRMR
Wall Street analysts forecast LRMR stock price to rise
4 Analyst Rating
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.660
Low
21.00
Averages
21.50
High
22.00
Current: 3.660
Low
21.00
Averages
21.50
High
22.00
About LRMR
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA is a rare, progressive, and fatal disease in which patients are unable to produce sufficient FXN due to a genetic abnormality. Its CPP platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company intends to use its proprietary platform to target additional orphan indications characterized by deficiencies in or alterations of intracellular content or activity.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Larimar Submits Biologics License Application for Nomlabofusp
- FDA Meeting Confirmation: Larimar received confirmation from the FDA during a Type B multidisciplinary meeting that its existing data package is sufficient to support the Biologics License Application (BLA) for nomlabofusp, with remaining modules expected to be submitted in the second half of 2026, marking a significant advancement in the accelerated approval pathway.
- Positive Clinical Data: In the ongoing long-term open-label study, participants achieved and maintained skin FXN levels comparable to 50% of healthy volunteers at both 1 year and 18 months, with 100% of participants sustaining these levels, indicating the treatment's efficacy and potential clinical benefits.
- Improvement in Clinical Outcomes: Among participants treated with nomlabofusp, a mean improvement of 1.0 points in mFARS was observed at 1 year, while the FACOMS reference group experienced a 1.6-point worsening, highlighting the potential of nomlabofusp to improve clinical outcomes in patients with Friedreich's ataxia.
- Good Safety Profile: Long-term dosing of nomlabofusp demonstrated good tolerability, with 10 out of 43 patients experiencing allergic reactions; however, all patients returned to their usual health, confirming the drug's safety and tolerability in clinical applications.
See More
Larimar Submits Biologics License Application for Friedreich's Ataxia Treatment
- FDA Meeting Outcome: Following a multidisciplinary Type B meeting with the FDA, Larimar submitted the first module of its biologics license application, with the FDA indicating that the existing data package may support accelerated approval, which sets the stage for future market access as the company plans to submit remaining modules in the second half of 2026.
- Clinical Data Highlights: Patients treated with nomlabofusp showed sustained increases in skin frataxin levels over one year, with all nine evaluable participants achieving frataxin levels above 50% of the average seen in healthy volunteers, demonstrating the treatment's efficacy and potential market competitiveness.
- Commercialization Plans: If approved, Larimar aims for a mid-2027 commercial launch of its treatment and plans to dose the first patient in its global confirmatory Phase 3 study in Q3 2026, indicating a proactive approach to future market positioning.
- Investor Sentiment: Despite a 4% decline in LRMR stock year-to-date, it has risen 19% over the past 12 months, with investor sentiment on Stocktwits trending in the 'extremely bullish' territory, reflecting optimism about the company's potential success.
See More
Larimar Therapeutics to Host Investor Event on Nomlabofusp Program
- Investor Event Announcement: Larimar Therapeutics has scheduled an investor event for June 29, 2026, at 7:45 a.m. ET to provide updates on its Nomlabofusp program for Friedreich's ataxia, aiming to attract more investor interest in potential treatment solutions in this area.
- Clinical Research Updates: During the event, the company will share regulatory updates and data from the ongoing Phase 2 long-term open-label study of Nomlabofusp, which will provide investors with critical insights into clinical trial progress and enhance market confidence in its product.
- Market Performance Review: LRMR stock has traded between $2.71 and $6.42 over the past year, closing at $3.66, up 4.57% from the previous trading day, indicating a positive market response to its future potential.
- Future Development Strategy: Larimar plans to leverage its intracellular delivery platform to design fusion proteins targeting other rare diseases, which not only showcases the diversity of its technology but also opens new market opportunities, further driving business growth.
See More
Larimar Therapeutics to Host Investor Event on Clinical Updates
- Investor Event Announcement: Larimar Therapeutics will host an investor event on June 29, 2026, at 7:45 AM ET to discuss updates on its nomlabofusp clinical development program, including regulatory updates and data from the long-term open-label study, aimed at enhancing investor confidence in the company's future prospects.
- Clinical Research Focus: The event will highlight advancements in the treatment for Friedreich's ataxia, with nomlabofusp as the company's lead candidate, which, if successful, could provide new treatment options for patients with rare diseases and significantly enhance the company's market position in the biotechnology sector.
- Webcast Access: Investors can access the live webcast of the event through the company's website, and an archived version will be available on the
See More
Biotech Companies See Significant Stock Gains
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
Larimar Submits Biologics License Application for Nomlabofusp
- FDA Meeting Confirmation: Larimar received confirmation from the FDA during a Type B multidisciplinary meeting that its existing data package is sufficient to support the Biologics License Application (BLA) for nomlabofusp, with remaining modules expected to be submitted in the second half of 2026, marking a significant advancement in the accelerated approval pathway.
- Positive Clinical Data: In the ongoing long-term open-label study, participants achieved and maintained skin FXN levels comparable to 50% of healthy volunteers at both 1 year and 18 months, with 100% of participants sustaining these levels, indicating the treatment's efficacy and potential clinical benefits.
- Improvement in Clinical Outcomes: Among participants treated with nomlabofusp, a mean improvement of 1.0 points in mFARS was observed at 1 year, while the FACOMS reference group experienced a 1.6-point worsening, highlighting the potential of nomlabofusp to improve clinical outcomes in patients with Friedreich's ataxia.
- Good Safety Profile: Long-term dosing of nomlabofusp demonstrated good tolerability, with 10 out of 43 patients experiencing allergic reactions; however, all patients returned to their usual health, confirming the drug's safety and tolerability in clinical applications.
See More
Larimar Submits Biologics License Application for Friedreich's Ataxia Treatment
- FDA Meeting Outcome: Following a multidisciplinary Type B meeting with the FDA, Larimar submitted the first module of its biologics license application, with the FDA indicating that the existing data package may support accelerated approval, which sets the stage for future market access as the company plans to submit remaining modules in the second half of 2026.
- Clinical Data Highlights: Patients treated with nomlabofusp showed sustained increases in skin frataxin levels over one year, with all nine evaluable participants achieving frataxin levels above 50% of the average seen in healthy volunteers, demonstrating the treatment's efficacy and potential market competitiveness.
- Commercialization Plans: If approved, Larimar aims for a mid-2027 commercial launch of its treatment and plans to dose the first patient in its global confirmatory Phase 3 study in Q3 2026, indicating a proactive approach to future market positioning.
- Investor Sentiment: Despite a 4% decline in LRMR stock year-to-date, it has risen 19% over the past 12 months, with investor sentiment on Stocktwits trending in the 'extremely bullish' territory, reflecting optimism about the company's potential success.
See More
Larimar Therapeutics to Host Investor Event on Nomlabofusp Program
- Investor Event Announcement: Larimar Therapeutics has scheduled an investor event for June 29, 2026, at 7:45 a.m. ET to provide updates on its Nomlabofusp program for Friedreich's ataxia, aiming to attract more investor interest in potential treatment solutions in this area.
- Clinical Research Updates: During the event, the company will share regulatory updates and data from the ongoing Phase 2 long-term open-label study of Nomlabofusp, which will provide investors with critical insights into clinical trial progress and enhance market confidence in its product.
- Market Performance Review: LRMR stock has traded between $2.71 and $6.42 over the past year, closing at $3.66, up 4.57% from the previous trading day, indicating a positive market response to its future potential.
- Future Development Strategy: Larimar plans to leverage its intracellular delivery platform to design fusion proteins targeting other rare diseases, which not only showcases the diversity of its technology but also opens new market opportunities, further driving business growth.
See More
Larimar Therapeutics to Host Investor Event on Clinical Updates
- Investor Event Announcement: Larimar Therapeutics will host an investor event on June 29, 2026, at 7:45 AM ET to discuss updates on its nomlabofusp clinical development program, including regulatory updates and data from the long-term open-label study, aimed at enhancing investor confidence in the company's future prospects.
- Clinical Research Focus: The event will highlight advancements in the treatment for Friedreich's ataxia, with nomlabofusp as the company's lead candidate, which, if successful, could provide new treatment options for patients with rare diseases and significantly enhance the company's market position in the biotechnology sector.
- Webcast Access: Investors can access the live webcast of the event through the company's website, and an archived version will be available on the
See More
Biotech Companies See Significant Stock Gains
- Regentis Stock Surge: Regentis Biomaterials Ltd. shares soared over 88% as the company prepares to commence European Surgeon Training for GelrinC in Q3 2026, accelerating its commercialization efforts in knee cartilage repair and enhancing its competitive edge in the market.
- Eloxx Uplisting Success: Eloxx Pharmaceuticals Inc. saw its stock rise more than 77% after uplisting to Nasdaq, with plans to issue 2.975 million shares at $11.00 each, expected to generate $66 million in revenue, supporting its clinical trials for Alport syndrome treatment.
- Alignment Healthcare Gains: Alignment Healthcare Inc. shares increased over 25% following disclosures of RSU grants to executives, with projected Q2 2026 revenues between $1.295 billion and $1.315 billion, indicating strong growth potential in the healthcare sector.
- Cartesian Strategic Licensing: Cartesian Therapeutics Inc. inked a strategic licensing deal with WestGene Biopharma to advance CAR-T therapies for autoimmune diseases, with a Phase 1 trial expected to start in 2H 2026, potentially driving innovation in this therapeutic area.
See More
Wall Street's Latest Rating Changes Overview
- Openlane Upgrade: JPMorgan upgraded Openlane from neutral to overweight and raised its December 2026 price target to $38, indicating that the online used car marketplace is experiencing robust growth and has potential for sustainable expansion over the coming years.
- Dollar General Downgrade: Deutsche Bank downgraded Dollar General from buy to hold, citing challenges in its customer base and the widening gap in the K-shaped economy, which may limit same-store sales upside, reflecting a cautious outlook on the company.
- Ecolab Upgrade: UBS upgraded Ecolab from neutral to buy and raised its price target to $325, demonstrating strong demand and positive performance expectations for the chemicals company amid a favorable market environment.
- FedEx Upgrade: JPMorgan upgraded FedEx from neutral to overweight, expressing optimism ahead of its upcoming earnings report, particularly regarding the separation of its freight business, which is seen as an attractive risk-reward opportunity.
See More
